From Breakthroughs Blog: Guest Post

 
Neil Palmer/CIAT
Preparing the ground in the Brazilian Amazon for a new antimalarial to reduce relapse

Tackling malaria in the Brazilian Amazon has proved challenging. But furtunetly, a solution could be in sight.

Read More
PATH/Katrina Peach
TB epidemic looms large in era of declining R&D funding

October 2016 delivered two sobering wake-up calls: The tuberculosis (TB) epidemic is larger than many realized, and TB R&D has has fallen to its lowest level in seven years.

Read More
Rob Oxley/DFID
DFID lays out vision to tackle global challenges through investments in research

The United Kingdom’s Department for International Development released it’s first-ever research review, laying out a vision for how it will invest £390 million in research and technology per year over the next four years to tackle the world’s toughest challenges.

PATH
Read More
GHTC/Matthew Robinson
The world commits to the AMR fight

At the United Nations General Assembly, world leaders made an unprecedented collective commitment to fighting the growing problem of antimicrobial resistance. GHTC and Global Health Council analyze what that commitment entails, why it matters, and the importance of what happens next.

Global Health Council
Read More
US Centers for Disease Control and Prevention
New information for innovation: Antimicrobial Resistance Isolate Bank

A new tool from the US Centers for Disease Control and Prevention is helping researchers develop diagnostic tests and antibiotics to combat the growing problem of antibiotic resistance.

Read More
Courtney Carson/GHTC
From DC to Atlanta: Becoming Better Advocates for CDC Global Health Programs on Capitol Hill

Global health advocates traveled to the US Centers for Disease Control and Prevention last month. Here's what they learned about the agency's work.

Global Health Council
Read More
PATH/Evelyn Hockstein
Progress report on health R&D: A Q&A with USAID

USAID's Neal Brandes answers our questions about the agency's latest Health-Related Research and Development Progress Report and USAID's ongoing support for global health R&D.

Read More
Funding by crisis is no cure for global health threats

The Zika virus outbreak reinforces the need for US policymakers to stop funding by crisis and commit to sustainable, long-term investment in global health R&D.

Read More
A vaccine is essential to conclusively end HIV/AIDS: New modeling data catalyzes conversations around the end of HIV/AIDS and a vaccine’s role in getting there

In this guest post Tom Harmon, senior policy analyst at the International AIDS Vaccine Initiative (IAVI), highlights a new analysis exploring the critical role of a vaccine in ending AIDS.

Read More
New affordable oral cholera vaccine receives WHO prequalification

In January, GHTC member International Vaccine Institute (IVI) announced that a new oral cholera vaccine it developed in partnership with Korean biotech company EuBiologics, Co. Ltd.—Euvichol®—received prequalification from the World Health Organization (WHO), paving the way for the vaccine to be purchased by global procurement bodies like Gavi, the Vaccine Alliance and UNICEF.

Read More
Welcoming the National Action Plan for Combating Multidrug-Resistant Tuberculosis: Important first steps, critical next steps

In this guest post, Dara Erck, vice president of external affairs at Aeras, discusses the new White House National Action Plan for Combating Multidrug-Resistant Tuberculosis and how it could accelerate research and development (R&D) of new technologies to combat multidrug-resistant TB (MDR-TB).

Aeras
Read More
A second chance for a TB research movement

In this guest post, Mike Frick, TB/HIV project officer at the Treatment Action Group (TAG), reflects on activist calls for greater investment in tuberculosis (TB) research and development (R&D) at the 46th Union World Conference on Lung Health and the stagnation of global TB R&D funding at a time of growing drug resistance.

Read More
DNDi/João Roberto Ripper
Chagas disease: A silent kiss and a neglected killer

Valentine’s Day seems like a fitting occasion to shine some needed light on a disease that can begin with a late-night “kiss” but ends with a broken heart.

Read More
#CoughUpTheTBMoney: TB activists call for tripling annual spending on TB research

In this guest post, Mike Watson Frick—TB/HIV program officer at Treatment Action Group (TAG)—writes about the state of tuberculosis (TB) research funding and civil society actions that took place at the recent Union World Conference on Lung Health in Barcelona, Spain.

Read More
Making the case for research and innovation for health in the post-2015 development agenda

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper exploring why research and development (R&D) of high-priority health tools for diseases and conditions affecting low- and middle-income countries (LMICs) should be a critical component of the post-2015 development agenda.

PATH
Read More
Why invest in R&D for HIV, TB and malaria? Because it’s good for global health, and good for Europe

In this post, Eoghan Walsh—communications officer at Deutsche Stiftung Weltbevoelkerung (DSW)—writes about the need for Europe to increase financial and political support for efforts aimed at creating new ways to tackle diseases such as HIV/AIDS, tuberculosis (TB) and malaria.

Read More
A new era for malaria treatment

In this post, PATH Vice President of Product Development, David Kaslow, writes about the first-ever shipment of semisynthetic artemisinin (ssART)—a new type of malaria treatment that marks a significant milestone in the fight against malaria.

Read More
European and African countries meet to advance health technology development for poverty-related diseases

Earlier this week, Anne Hradský—advocacy coordinator for Global Health Research and Development (R&D), Katharina Scheffler—advocacy officer—and others from Deutsche Stiftung Weltbevoelkerung (DSW)—joined other European and African stakeholders for the Seventh European & Developing Countries Clinical Trials Partnerships (EDCTP) Forum in Berlin, Germany.

Read More
EDCTP2: What it means for European support for global health R&D

In this guest post, Renate Baehr—executive director of Deutsche Stiftung Weltbevoelkerung—writes about the next rendition of the European & Developing Countries Clinical Trials Partnership (EDCTP) and how its expansion will impact more lives in low- and middle-income countries.

Read More
A new Lab to harness the power of innovation

In this guest post, Heather Ignatius—senior policy and advocacy officer at PATH—writes about the new Global Development Lab at the US Agency for International Development (USAID).

PATH
Read More
Public-private partnerships: Where have we been and where do we go?

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a series of dialogues PATH and other partners convened to discuss public-private partnerships for global health product development.

PATH
Read More
TB free breathing in the mines of South Africa: New TB vaccines could transform mining across the region

In this guest post, Kari Stoever, vice president of External Affairs at Aeras, writes about how mine workers are disproportionately affected by tuberculosis (TB) and why there’s an urgent need for new tools against this deadly disease.

Aeras
Read More
The human face of global health R&D: Cynthia Gama and USAID

The US Agency for International Development (USAID) is the nation’s lead foreign assistance agency.

GHTC
Read More
The human face of global health R&D: Brian D’Cruz and USAID

The US Agency for International Development (USAID) is the nation’s lead foreign assistance agency.

GHTC
Read More
Investing in R&D for neglected diseases: Three investment patterns that put lives at risk

In this guest post, Dr. Mary Moran—executive director—and Dr. Penny Farrell—analyst—from Policy Cures shares key findings from the recently released G-FINDER survey.

Policy Cures
Policy Cures
Read More
European action on TB vaccines

In this guest post, Kari Stoever—vice president of External Affairs at Aeras—writes about European support for new vaccines against tuberculosis (TB).

Aeras
Read More
Improving the affordability, availability, and acceptability of health technologies for low- and middle-income countries

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper she developed for the GHTC that outlines key issues surrounding access to global health products.

PATH
Read More
The end of AIDS requires increased commitments to research

In this guest post, Anupama Dathan—health research assistant for ONE—writes about a new report that examines global commitments to ending the AIDS pandemic.

ONE
Read More
TAG/Hollander Snow Studio
Funding for TB research drops for the first time in eight years

Each year since 2006, TAG has tracked spending on research and development (R&D) for new diagnostics, drugs, and vaccines to improve TB treatment and prevention.

Read More
Vaccinate against the brain drain

In this guest post, Elisabeth Wilhelm, senior media specialist at the International AIDS Vaccine Initiative (IAVI), writes about the need to invest in the next generation of researchers and scientists in sub-Saharan Africa.

Read More
New paper examines research funding for diseases and conditions of poverty

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper she developed for the GHTC that outlines key funding challenges and opportunities for global health research and development (R&D).

PATH
Read More
What comes to mind when you think of drug development?

Ever feel like you can’t see the forest for the trees?

GHTC
Read More
PATH/Elena Pantjushenko
Drug development—It’s not for the faint of heart

Drug discovery and development is a long process. Estimates of the cost to develop a drug up to the point of regulatory approval can range from $150 million to $1.3 billion.

PATH
Read More
Telling the untold story of tuberculosis

In this guest post, Kari Stoever, vice president of External Affairs at Aeras, writes about a new film series that tells the story of the tuberculosis (TB) pandemic.

Aeras
Read More
New paper offers insights into key challenges facing R&D for diseases of poverty

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper she developed for the GHTC that outlines key challenges and solutions facing research and development (R&D) for diseases of poverty.

PATH
Read More
Asking the right research questions to achieve global health goals

In this guest post, Kristina Gryboski—technical advisor for the Child Survival and Health Grants Program at the US Agency for International Development (USAID)—writes about the importance of partnerships to advance health research.

Read More
PATH/Eric Becker
Creating partnerships for innovative, high-impact global health products

For more than 30 years, PATH has been working to advance innovative global health solutions. Partnering is a core part of PATH’s strategy and is fundamental to how we develop and deliver high-impact, cost-effective technologies.

PATH
Read More
PATH/Aaron Joel Santos
Film series highlights need for new TB vaccines worldwide

Aeras is excited to share the trailer for a series of short films exposing the underreported global epidemic of TB and the movement for innovation to improve our tools to fight it.

Aeras
Read More
Microbicides, vaccines, and TB diagnostics Oh my! What’s new in HIV/AIDS research?

In this guest post, Molly Schmalzbach—public affairs analyst in the Office of HIV/AIDS at the US Agency for International Development (USAID)—discusses the agency’s support for research to develop new HIV/AIDS and tuberculosis (TB) products.

Read More
PATH/Evelyn Hockstein
Global health research and development: Advancing women’s right to health

On this day honoring the political, social, and economic contributions women have made worldwide, nearly 2,000 women will die of AIDS and 790 will perish in pregnancy or childbirth. If we wish to truly advance the health and rights of women globally, we must give them the tools they need to protect their own health.

Read More
PATH
Developing new tools to fight TB: New report examines state of TB R&D

Mycobacterium tuberculosis is one of the oldest known human pathogens that continues to pose a global public health threat in the 21st century.

Treatment Action Group
Read More
The Financial Times highlights global successes and the remaining challenges in combating NTDs

In this guest post, Richard Hatzfeld, communications director for the Sabin Vaccine Institute, writes about a special report on neglected tropical diseases in the Financial Times, and the need for increased research, partnerships, and support to combat these diseases.

Sabin Vaccine Institute
Read More